Literature DB >> 11932036

The diagnostic interval in amyotrophic lateral sclerosis.

Yasuo Iwasaki1, Ken Ikeda, Yasumitsu Ichikawa, Osamu Igarashi, Masao Kinoshita.   

Abstract

We studied whether there are any parameters that influence the period between onset of symptoms and confirmation of diagnosis in 117 patients with ALS (65 male, 52 female). The mean age of diagnosis was 57 years for men and 59 years for women. Bulbar-onset patients were older at diagnosis than limb-onset patients both men and women. Patients with bulbar-onset appeared to be more frequent in women (33:19). Contrariwise, limb-onset patients were more frequently male (43:22). The time to confirmation was much shorter with symptoms of bulbar-onset (10.5 months in male, 9.8 months in female) than for those with limb-onset (13.7 months in male, 14.8 months in female) in male, respectively, female ALS patients. The diagnosis of ALS was established in all cases by neurologists in our study.

Entities:  

Mesh:

Year:  2002        PMID: 11932036     DOI: 10.1016/s0303-8467(01)00188-3

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).

Authors:  Sabrina Paganoni; Eric A Macklin; Alexandra Lee; Alyssa Murphy; Judith Chang; Amanda Zipf; Merit Cudkowicz; Nazem Atassi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-07-01       Impact factor: 4.092

Review 2.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

3.  Minimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners.

Authors:  Martin Matharan; Stéphane Mathis; Sarah Bonabaud; Louis Carla; Antoine Soulages; Gwendal Le Masson
Journal:  Neurol Res Int       Date:  2020-05-11

4.  Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study.

Authors:  Ryuji Kaji; Takashi Imai; Yasuo Iwasaki; Koichi Okamoto; Masanori Nakagawa; Yasuo Ohashi; Takao Takase; Takahisa Hanada; Hiroki Shimizu; Kunio Tashiro; Shigeki Kuzuhara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-01-13       Impact factor: 10.154

5.  Limb-onset amyotrophic lateral sclerosis patients visiting orthopedist show a longer time-to-diagnosis since symptom onset.

Authors:  Osamu Kano; Konosuke Iwamoto; Hirono Ito; Yuji Kawase; Derek Cridebring; Ken Ikeda; Yasuo Iwasaki
Journal:  BMC Neurol       Date:  2013-02-09       Impact factor: 2.474

6.  Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.

Authors:  Ching-Hua Lu; Axel Petzold; Jo Topping; Kezia Allen; Corrie Macdonald-Wallis; Jan Clarke; Neil Pearce; Jens Kuhle; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Linda Greensmith; Andrea Malaspina
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-07-09       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.